Videos

Longer follow-up and real-world claims data add context that pivotal trials alone cannot provide. The panel examines both, alongside how monitoring for response actually happens in daily practice.

A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this antipsychotic therapy was studied and what its data actually show.

Bleeding fears, skipped doses, and cost leave many patients with atrial fibrillation unprotected from stroke. A cardiologist and vascular medicine specialist explains.

See how PrEP blocks HIV, who benefits most, and why access gaps hit women, youth, and the South—plus ways to close them.

Explore how retatrutide, amylin therapies, and oral agents could expand obesity treatment beyond semaglutide and tirzepatide.

Geoffrey Barnes, MD, on why a careful exam is the first line of detection and which 2 risk factors primary care clinicians can actually change.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

Daniel Drucker, MD, discusses gastrointestinal effects, hydration, pregnancy planning, and unanswered long-term safety questions.

An endocrinologist discusses the importance of history, comorbidities, lifestyle care, and outcomes beyond weight loss when choosing obesity treatment.

Pamela Kushner, MD, explains why smartwatches and other cuffless monitors remain unvalidated for hypertension diagnosis and management.

Pamela Kushner, MD, outlines why clinical inertia and improper blood pressure measurement fuel the nation's control gap.

Daniel Drucker, MD, who coauthored the recent Endocrine Society scientific statement on obesity medicines, discusses key takeaways for primary care physicians.

Two on-label options are not enough for every patient. The panel weighs the field's remaining unmet needs against the biological rationale behind a newer, non-antipsychotic approach to treatment.

Decades of off-label prescribing for agitation associated with dementia due to Alzheimer’s are colliding with new evidence and new regulation. The panel examines why practice has lagged behind the data, and what is now changing.

Joshua LaBaer, PhD, reviews a national study he led that linked pre-existing antimicrobial antibodies with subsequent COVID-19 vaccine response.

Mina Fam, MD, addresses common prostate cancer misconceptions involving symptoms, elevated PSA, biopsy, and active surveillance.

Mina Fam, MD, reviews risk-based PSA interpretation, prostate MRI, biomarkers, and targeted biopsy in the modern diagnostic pathway.

Rodica Di Lorenzo, MD, explains why new headaches, migraine with aura, estrogen exposure, smoking, and pregnancy matter in stroke assessment.

A urologist discusses how primary care clinicians can identify patients most likely to benefit from prostate cancer screening while limiting overdiagnosis.

Before any prescription is written, non-pharmacologic strategies and a structured framework guide the panel's approach to agitation, alongside a biological explanation for why redirection so often fails.

Agitation does not stay contained to the patient. The panel examines the data linking agitation to caregiver burden, and the communication gaps that complicate coordinating care across specialties.

Brief speech, motor, vision, or balance changes may signal a TIA and require urgent evaluation, Rodica Di Lorenzo, MD, tells Patient Care Online.

Rodica Di Lorenzo, MD, of the Cleveland Clinic, reviews hypertension, lipids, diabetes, smoking, atrial fibrillation, and wearables in first-stroke prevention.

In "Improving Shared Decision-Making in Endometriosis Care," the panel opens Section 3 by asking why medical management still lags in everyday practice.

Experts weigh GLP-1 therapy's promise for PMOS against the risks of overly rapid weight loss in teenagers.

Experts break down which labs actually change PMOS management and how to avoid diagnostic pitfalls.

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.